New trends in the treatment of diabetic nephropathy in children

Bibliography

• CHIARELLI F, VERROTTI A, BASCIANI F et al.: Controversies on the prevention of diabetic nephropathy." Pediatr. Endocrine]. Metab. (1998) 11:365–368.
   Google Scholar
• THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl. J. Med. ( 1993) 329:977–986.
   PubMed Web of Science ®Google Scholar
• ••The most important longitudinal study ondiabetes in childhood.
   Google Scholar
• BOJESTIG M, ARNQVIST HJ, HERMANSSON G, KARLBERG BE, LUDVIGSSON J: Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl. J. Med. (1994) 330:15–18.
   PubMed Web of Science ®Google Scholar
• MACKENZIE HS, BRENNER BM: Current strategies for retarding progression of renal disease. Am. j Kidney Dis. (1998) 31:161–170.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY GROUP: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with Type 2 diabetes. Lancet (1998) 352:837–853.
   PubMed Web of Science ®Google Scholar
• HOVIND P, ROSSING P, TARNOW L, SMIDT UM, PARVING HH: Remission and regression in the nephropathy of Type 1 diabetes when blood pressure is controlled aggressively. Kidney Int. (2001) 60:277–283.
   PubMed Web of Science ®Google Scholar
• MOGENSEN CE: Definition of diabetic renal disease in insulin-dependent diabetes mellitus based on renal function tests. In: The kidney and hypertension in diabetes mellitus. (Ed.) Kluwer Academic Publishers (1994) 1(4)1-14. An extensive review of diabetic renal disease.
   Google Scholar
• COOPER ME: Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet (1998) 352:213–219.
   PubMed Web of Science ®Google Scholar
• CHIARELLI F, CASANI A, TUMINI S, KORDONOURI 0, DANNE T: Diabetic nephropathy in childhood and adolescents. Diabetes Nutr. Metab. (1999) 12:144–153.
   PubMedGoogle Scholar
• BAKRIS GL, WILLIAMS M, DWORKIN L, ELLIOTT WJ, EPSTEIN M, TOTO R et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. I Kidney Dis. (2000) 36:646–661.
   PubMed Web of Science ®Google Scholar
• GULMANN C, RUDBERG S, NYBERG G, OSTERBY R: Enlargement of the juxtaglomerular apparatus in insulin-dependent diabetes mellitus patients with microalbuminuria. Virchusvs Arch. (1998) 433:63–67.
   PubMedGoogle Scholar
• POULSEN PL, HANSEN KW, MOGENSEN CE: Ambulatory blood pressure in the transition from normo- to microalbuminuria; a longitudinal study in IDDM patients. Diabetes (1994) 43:1248–1253.
   PubMedGoogle Scholar
• DECKERT T, KOFOED-ENEVOLDSEN A, VIDAL P, NORGAARD K, ANDREASEN HB, FELDT-RASMUSSEN B: Size- and charge-selectivity of glomerular filtration in IDDM patients with and without albuminuria. Diabetologia (1993) 36:244–251.
   PubMed Web of Science ®Google Scholar
• SCHRIER W, ESTACIO RO, JEFFERS BW et al: Appropriate blood pressure control in diabetes. Part 2 with valsartan. Am.Hypertens. (1999) 12 (Part 2)141A.Abstract E010.
   Google Scholar
• OSTERBY R, BANGSTAD HJ, RUDBERG S: Follow-up study of lomerular dimensions and cortical interstitium in microalbuminuric Type 1 diabetic patients with or without antihypertensive treatment. Nephrol Dial. Transplant. (2000) 15:1609–1616.
   PubMed Web of Science ®Google Scholar
• ELLIOTT WJ, MADDY R, TOTO R, BAKRIS G: Hypertension in patients with diabetes. Overcoming barriers to effective control. Partgrad. Med. (2000) 107:29–36.
   Google Scholar
• COLLADO-MESA F, COLHOUN HM, STEVENS LK et al.: Prevalence and management of hypertension in Type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study. Diabet. Med. 1999:16:41–48.
   PubMed Web of Science ®Google Scholar
• SCHULTZ CJ, NEIL HA, DALTON RN, KONOPELSKA BT, DUNGER DB: Blood pressure does not rise before the onset of microalbuminuria in children followed from diagnosis of Type 1 diabetes. Oxford Regional Prospective Study Group. Diabetes Care (2001) 24:555–560.
   PubMed Web of Science ®Google Scholar
• GULMANN C, RUDBERG S, OSTERBY R: Renal arterioles in patients with Type I diabetes and microalbuminuria before and after treatment with antihypertensive drugs. Virchows Arch. (1999) 434:523–528.
   PubMedGoogle Scholar
• GULMANN C, OSTERBY R, BANGSTAD HJ, RUDBERG S: The juxtaglomerular apparatus in young type-1 diabetic patients with microalbuminuria. Effect of antihypertensive treatment. Virchows Arch. (2001) 438:618–623.
   PubMedGoogle Scholar
• PARVING HH, ANDERSEN et al.: Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br. Med. J. (1987) 294:1443–1447.
   PubMedGoogle Scholar
• MOGENSEN CE: Long-term anti-hypertensive treatment inhibiting progression of diabetic nephropathy. Br. Med. J. (1982) 285:685–688.
   PubMed Web of Science ®Google Scholar
• ZATZ R, DUNN BR, MEYER TW, ANDERSON S, RENNKE HG, BRENNER BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. j. Clin. Invest. (1986) 77:1925–1930.
   PubMed Web of Science ®Google Scholar
• CHATURVEDI N, SJOLIE AK, STEPHENSON JM et al.:Effect of lisinopril on progression of retinopathy in normotensive people with Type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet (1998) 351:28–31.
   Google Scholar
• THE EUCLID STUDY GROUP: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet (1997) 349:1787–1792.
   PubMed Web of Science ®Google Scholar
• MARRE M, CHATELLIER G, LEBLANC H et al.: Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br. Med. J. (1988) 297:1092–1095.
   PubMed Web of Science ®Google Scholar
• RUDBERG S, OSTERBY R, BANGSTAD HJ, DAHLQUIST G, PERSSON B: Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with Type I (insulin-dependent) diabetes mellitus. Diabetologia (1999) 42:589–595.
   PubMed Web of Science ®Google Scholar
• MOGENSEN CE, NELDAM S, TIKKANEN I et al: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. (2000) 321:1440–1444.
   PubMed Web of Science ®Google Scholar
• GOLIGORSKY MS, CHEN J, BRODSKY S: Workshop: endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension (2001) 37:744–748.
   PubMed Web of Science ®Google Scholar
• CHIARELLI F, CIPOLLONE F, ROMANO F et al.: Increased circulating nitric oxide in young patients with Type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration. Diabetes (2000) 49:1258–1263.
   PubMed Web of Science ®Google Scholar
• HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet (2000) 355:253–259.
   PubMed Web of Science ®Google Scholar
• O'HARE P, BILBOUS R, MITCHELL T et al.: Low-dose ramipril reduces microalbuminuria in Type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care (2000) 23:1823–1829.
   Google Scholar
• Should all patients with Type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann. Intern. Med. (2001) 134:370–379.
   PubMedGoogle Scholar
• APPERLOO AJ, DE ZEEUW D, DE JONG PE: A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int. (1997) 51:793–797.
   PubMed Web of Science ®Google Scholar
• SCHOOLWERTH AC, SICA DA, BALLERMANN BJ, WILCOX CS: Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High blood pressure Research of the American Heart Assoc-iation. Circulation (2001) 104:1985–91.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, DENG LY, LAROCHELLE P: Effects of antihypertensive treatment on vascular remodeling in essential hypertensive patients.j Cardiovasc. Pharmacol (1994) 24\(Suppl. 3):551–556.
   Google Scholar
• CHIARELLI F, CASANI A, VERROTTI A, MORGESE G, PINELLI L: Diabetic nephropathy in children and adolescents: a critical review with particular reference to angiotensin-converting enzyme inhibitors. Acta Paediatr. Sapp]. (1998) 425:42–45.
   Google Scholar
• NAKAYA H, SASAMURA H, KITAMURA Y et al.: Effect of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis. Hypertens. Res. (1999) 22:303–312.
   PubMed Web of Science ®Google Scholar
• RITZ E, RYCHLIK I, MILTENBERGER-MILTENYI G: Optimizing antihypertensive therapy in patients with diabetic nephropathy. Hypertens. (1998) 16\(Suppl. 7):517–522.
   Google Scholar
• COOK J, DANEMAN D, SPINO M, SOCHETT E, PERLMAN K, BALFE JW: Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin dependent diabetes mellitus. " Pediatr. (1990) 117:39–45.
   PubMedGoogle Scholar
• CHIARELLI F, VERROTTI A, MAGRI M, MORGESE G: Angiotensin converting enzyme inhibition in normotensive diabetic adolescents with persistent micro-albuminuria. Horn]. Res. (1996) 46:3–6.
   Google Scholar
• RUDBERG J, APERIA A, FREYSCHUSS U, PERSSON B: Enalaptil reduces microalbuminuria in young normotensive patients irrespective of its hypotensive effect. Diabetologia (1990) 33:470–476.
   PubMed Web of Science ®Google Scholar
• SOFFER BA, SHAHINFAR S, SHAW WC et al.: Effects of the ACE inhibitor, enalapril, in children age 6-16 years with hypertension. Pediatr. Res. (2000) 47:452A.
   Google Scholar
• SHAHINFAR S, RIPPLEY R, HOGG RJ et al.: Multicenter study of enalapril pharmacokinetics in hypertensive children and infants. Pediatr. Res. (2000) 47:473A.
   Google Scholar
• MIRKIN BL, NEWMAN TJ: Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. Pediatrics (1985) 75:1091–1100.
   PubMed Web of Science ®Google Scholar
• CASANI A, BANGSTAD HJ, CHIARELLI F: Detection and manage-ment of diabetic glomerulopathy in children and adolescents with insulin-dependent diabetes mellitus: need for improved knowledge and better care. j. Pediatr. Endocrinol Metab. (2000) 13:467–474.
   PubMedGoogle Scholar
• WELLS TG, SINAIKO AR: Antihyper-tensive effect and pharmacokinetics of nitrendipine in children.j Pediatr. (1991) 118:638–643.
   PubMedGoogle Scholar
• TALLIAN KB, NAHATA MC, TURMAN MA: Efficacy of amlodipine in pediatric patients with hypertension. Pediatr. Nephrol (1999) 13:304–310.
   PubMed Web of Science ®Google Scholar
• MONCICA I, OH PI, UL QAMAR I et al:A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension. Arch. Dis. Child. (1995) 73:154–156.
   PubMedGoogle Scholar
• HEINEMANN L, JANICKE I, BENDER R, BERGER M, SAWICKI PT: Effect of enalapril and nitrendipine on exercise albuminuria in normotensive Type I diabetic patients with incipient nephropathy. Horm. Metab. Res. (1996) 28:549–552.
   PubMedGoogle Scholar
• MOSCONI L, RUGGENENTI P, PERNA A, MECCA G, REMUZZIG: Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int. Sapp]. (1996) 55:S91–S93.
   Google Scholar
• PINOL C, COBOS A, CASES A et a/.: Nitrendipine and enalapril in the treatment of diabetic hypertensive patients with microalbuminuria. Kidney Int. Sapp]. (1996) 55:S85–S87.
   Google Scholar
• JUNGMANN E, MALANYN M. MORTASAWI N et al: Effect of 1-year treatment with nitrendipine versus enalapril on urinary albumin and alpha 1-microglobulin excretion in microalbuminuric patients with Type 1 diabetes mellitus. A randomized, single-blind comparative study Arzneimittelferschung (1994)44:313–317.
   Google Scholar
• BRETZEL RG, BOLLEN CC, MAESER E, FEDERLIN KF: Nephroprotective effects of nitrendipine in hypertensive Type I and Type II diabetic patients. Am. Kidney Dis. (1993) 21:53–64.
   PubMed Web of Science ®Google Scholar
• KOPF D, SCHMITZ H, BEYER J, FRANK M, BOCKISCH A, LEHNERT H: A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy. Diab. Nuti: Metab. (2001) 14:245–252.
   PubMedGoogle Scholar
• OWEN CA, CAMPBELL EJ: Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition. Immune]. (1998) 160:1436–1443.
   PubMed Web of Science ®Google Scholar
• TOTO R: Angiotensin II subtype 1 receptor blockers and renal function. Arch. Intern. Med. (2001) 161:1492–1499.
   PubMedGoogle Scholar
• BURNIER M, BRUNNER HR: Angiotensin II receptor antagonists. Lancet (2000) 355:637–645.
   PubMed Web of Science ®Google Scholar
• KIRK JK: Angiotensin-II receptor antagonists: their place in therapy. Am. Fam. Physician. (1999) 59:3140–3148.
   PubMed Web of Science ®Google Scholar
• ZIAI F, OTS M, PRO VOOST AP et al: The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int. Sapp]. (1996) 57:S132–S136.
   Google Scholar
• LEWIS EJ, HUNSICKER LG, CLARKE WR et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N EngLJ Med. (2001) 345:851–860.
   PubMed Web of Science ®Google Scholar
• PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J et al: The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl. I Med. (2001) 345:870–878.
   PubMed Web of Science ®Google Scholar
• BRENNER BM, COOPER ME, DE ZEEUW D et al: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl. I Med. (2001) 345:861.
   PubMed Web of Science ®Google Scholar
• ANDERSEN S, TARNOW L, ROSSING P, HANSEN BV, PARVING HH: Renoprotective effects of angiotensin II receptor blockade in Type 1 diabetic patients with diabetic nephropathy. Kidney Int. (2000) 57:601–606.
   PubMed Web of Science ®Google Scholar
• SCHULTZ CJ, KONOPELSKA-BAHU T, DALTON RN et al.: Microalbuminuria prevalence varies with age, sex and puberty in children with Type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care (1999) 22:495–502.
   PubMed Web of Science ®Google Scholar